On April 2, 2026 Dxcover, a global leader in AI-enabled technologies, reported the presentation of multiple studies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in San Diego, California this month.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will present data as part of key sessions focused on Early Detection Approaches – specifically Stage I and II cancers, which can be treated when detected, but are elusive to other screening protocols. Matthew Baker, PhD, CEO & co-Founder of Dxcover, commented: "Cancer is detected too late because early signals are invisible to current clinical tools. The Dxcover approach analyzes the body’s earliest reactions to malignancy – a perfect complement to existing high specificity diagnostics."
Data presented at the conference represent results from studies designed to investigate the Dxcover platform’s clinical feasibility and performance capabilities:
90+% sensitivity reported consistently across stage I-IV colorectal (CRC), pancreatic, and ovarian cancers
Integration, comparative performance and considerations of CRC biomarkers and screening modalities
"It’s exciting to share our latest findings at the AACR (Free AACR Whitepaper) conference," says James Cameron, PhD, Dxcover Clinical Program Manager and co-author on each presentation. "These data demonstrate our commitment to improving patient outcomes with continued progress toward earlier cancer detection."
Dxcover AACR (Free AACR Whitepaper) presentations: #5115, #5116, #7616, #7617
(Press release, Dxcover, APR 2, 2026, View Source [SID1234664163])